Sign in

Herpes zoster and postherpetic neuralgia

Neuropathic pain · C8 · Reviewed by a board-certified pain physician on November 2, 2026

Bottom line

Prevent zoster with recombinant vaccine, then treat postherpetic neuralgia as localized neuropathic pain: topicals suit small areas and frail patients, and systemic drugs need renal dosing and anticholinergic caution.

Key points

  1. Allodynia is the signature finding. Pain from a stimulus that does not normally hurt, such as light touch on a healed dermatome, is allodynia; increased pain from a painful stimulus is hyperalgesia 1.
  2. Vaccinate after shingles, once it heals. CDC recommends two doses of recombinant zoster vaccine, 2–6 months apart, for immunocompetent adults 50 and older, whether or not they report prior zoster; there is no specific waiting period other than avoiding vaccination during an acute episode 2.
  3. Topicals fit localized pain. NeuPSIG 2025 ranks lidocaine 5% plasters and capsaicin as weak second-line options 3; its 2015 version allowed lidocaine first line in frail older patients 8. After falls, Beers advises avoiding antidepressants and antiepileptics unless safer alternatives are unavailable 7.
  4. Know the patch rules. Lidocaine 5%: no more than three patches at a time on intact skin, worn a maximum of 12 hours and then off for 12 4. Capsaicin 8% for postherpetic neuralgia: up to four systems for 60 minutes, no more often than every 3 months 5.
  5. Systemic first-line drugs need care. Gabapentinoids, SNRIs and TCAs are first-line for neuropathic pain 3. Pregabalin is renally dosed: up to 600 mg/day with normal clearance, 75–300 mg/day at CrCl 30–60 mL/min 6.
  6. Avoid strongly anticholinergic TCAs in older adults. Beers lists amitriptyline among antidepressants to avoid because it is highly anticholinergic, sedating and causes orthostatic hypotension 7.

Watch for

In older adults with falls, glaucoma or cognitive impairment, systemic choices carry real harm: avoid strongly anticholinergic TCAs, and start gabapentinoids low after checking renal function 67.

High-yield for the exam

  • Recombinant zoster vaccine is a two-dose series given 2–6 months apart 2.
  • A prior zoster episode is not a reason to skip or delay vaccination once healed 2.
  • Lidocaine patch absorption rises with treated area and wear time 4.
  • Capsaicin 8% reduces TRPV1-expressing nerve endings, which re-emerge over months 5.
  • Pregabalin at CrCl 15–30 mL/min: 25–150 mg/day; below 15: 25–75 mg/day 6.
  • NeuPSIG 2025: capsaicin 8% patches, capsaicin cream and lidocaine 5% plasters are weak second-line options; lidocaine evidence is very low certainty 3.
  • Hyperpathia is an abnormally painful, often explosive reaction, especially to repeated stimulation 1.
  • Capsaicin 8% must not be applied to broken skin; staff wear nitrile gloves during application 5.

Numbers to know

Item Value
Zoster vaccine age (immunocompetent) ≥50 years 2
Doses and interval 2 doses, 2–6 months apart 2
Capsaicin 8% for PHN 60 minutes, ≤4 systems 5
Lidocaine 5% patches ≤3, ≤12 h per 24 h 4
Pregabalin maximum, normal renal function 600 mg/day 6
Pregabalin at CrCl 30–60 mL/min 75–300 mg/day 6

Common traps

  • Waiting a year after shingles before vaccinating 2.
  • Calling light-touch-evoked pain "hyperalgesia" 1.
  • Using the diabetic-foot capsaicin time (30 minutes) for postherpetic neuralgia 5.
  • Starting pregabalin at full dose without checking creatinine clearance in an older adult 6.

Practise this topic

5 more questions on this topic in the full question bank, with explanations and sources.

Sources

  1. IASP Terminology. International Association for the Study of Pain. iasp-pain.org/resources/terminology/
  2. Centers for Disease Control and Prevention. Shingles vaccine recommendations. CDC, 2024. cdc.gov/shingles/hcp/vaccine-considerations
  3. Soliman N, et al. Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol, 2025. pubmed.ncbi.nlm.nih.gov/40252663/
  4. US Food and Drug Administration. LIDODERM (lidocaine patch 5%) prescribing information. DailyMed, 2023. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db0092f5-02
  5. US Food and Drug Administration. QUTENZA (capsaicin) 8% topical system prescribing information. DailyMed, accessed 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ffbbcb0-ad
  6. US Food and Drug Administration. LYRICA (pregabalin) prescribing information. DailyMed, accessed 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=60185c88-ec
  7. By the 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc, 2023. pmc.ncbi.nlm.nih.gov/articles/PMC12478568/
  8. Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol, 2015. pmc.ncbi.nlm.nih.gov/articles/PMC4493167/

Related topics

Independent study material for the ABA Pain Medicine exam, written and reviewed by a board-certified pain physician. Not medical advice; not affiliated with the American Board of Anesthesiology.